| Current Price | $210.81 | Mkt Cap | $11.0B |
|---|---|---|---|
| Open | $214.60 | P/E Ratio | 25.73 |
| Prev. Close | $210.81 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $209.34 - $215.92 | Volume | 363,278 |
| 52-Wk Range | $181.36 - $449.34 | Avg. Daily Vol. | 598,745 |
The Company is a global provider of solutions that advance the drug discovery and development process. It provides the animal research models required in research and development for new drugs, devices and therapies.
| Current Price | $210.81 | Mkt Cap | $11.0B |
|---|---|---|---|
| Open | $214.60 | P/E Ratio | 25.73 |
| Prev. Close | $210.81 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $209.34 - $215.92 | Volume | 363,278 |
| 52-Wk Range | $181.36 - $449.34 | Avg. Daily Vol. | 598,745 |
Read the most recent pitches from players about CRL.
Recs
DaytradingStars
(37.52)
Submitted: 6/14/2020 4:42:09 AM :
Start Price:
$179.09
NYSE:CRL Score:
-7.49
17 growth for 24 forward
Recs
TMFTripleOption
(< 20)
Submitted: 4/21/2020 11:15:59 PM :
Start Price:
$135.30
NYSE:CRL Score:
+21.74
Charles River Labs had its hand in 90% of FDA approved drugs last year. They are also building a lot of labs in China. Their demand will only continue to grow.
Recs
CMFTomato
(61.85)
Submitted: 12/15/2019 4:28:09 PM :
Start Price:
$123.48
NYSE:CRL Score:
+41.97
Charles River breeds and sells lab rats, mice, bunnies, guinea pigs of all shapes and sizes and in various states of sickness, health, obesity, and even already having had various clinical procedures and operations. This company's work is unpleasant, but essential for the clinical trials and research behind the groundbreaking treatments and therapies that allow us to live longer and healthier.
Find the members with the highest scoring picks in CRL.
tskephart (95.86) Score: +525.51
The Score Leader is the player with the highest score across all their picks in CRL.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| tskephart | 95.86 | 11/26/2008 |
|
3Y | $21.87 | +863.92% | +338.41% | +525.51 | 1 Comment | |
| dingo72 | 78.02 | 12/3/2008 |
|
3Y | $21.94 | +860.85% | +345.30% | +515.55 | 0 Comment | |
| 5st4 | 88.11 | 1/9/2009 |
|
NS | $23.91 | +781.68% | +316.62% | +465.06 | 0 Comment | |
| DFT2007 | 99.90 | 11/17/2008 |
|
NS | $23.35 | +802.83% | +343.22% | +459.60 | 0 Comment | |
| dog1350 | 78.07 | 12/11/2008 |
|
5Y | $24.17 | +772.20% | +327.57% | +444.63 | 0 Comment | |
| jackjjr | 72.22 | 11/17/2011 |
|
5Y | $28.96 | +627.94% | +202.83% | +425.10 | 0 Comment | |
| humenay | 66.94 | 12/23/2008 |
|
3Y | $24.67 | +754.52% | +333.90% | +420.62 | 0 Comment | |
| kagold | 84.53 | 10/4/2011 |
|
5Y | $27.68 | +661.60% | +244.42% | +417.18 | 0 Comment | |
| CMFGouldberg | 56.20 | 10/3/2011 |
|
5Y | $28.18 | +648.08% | +239.47% | +408.61 | 0 Comment | |
| elzbal | 20.94 | 10/17/2011 |
|
1Y | $29.43 | +616.31% | +208.21% | +408.10 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
